

SAN SEBASTIÁN

INTERNATIONAL GENITOURINARY CANCER SUMMIT 2026

CUTTING-EDGE PERSPECTIVES IN GU CANCERS:
BLADDER, KIDNEY & PROSTATE

Global faculty, rigorous science, and real-world cases.
Actionable updates for GU oncology practice.

SAN SEBASTIÁN

SPAIN

25 - 26

JUNE

2026

PRELIMINARY AGENDA

Organizado



Excelencia
y Calidad en
Oncología

**Coordinación
Científica**



Avales Académicos

SEOM
Sociedad Española
de Oncología Médica

SEOM® es una marca registrada.
El aval de SEOM no implica la
organización ni financiación del evento.



GONORTE
Grupo Oncológico



GUARD CONSORTIUM
GU-Alliance for Research and Development



08:45 – 09:00

Welcome & Opening Remarks
Goals & Vision of SSIGS 2026



Chair

Dr. Andrea Apolo

Medical Oncologist. Physician-Scientist

Specialized in bladder cancer research, Maryland, USA



Chair

Dr. Enrique Grande

Medical Oncologist

Specialized in genitourinary and endocrine tumors, Madrid, Spain

09:00 – 10:00

BLOCK 1 – BLADDER CANCER

NMIBC & MIBC in 2026: Local vs Systemic Approaches
(Debate Edition)

Debate 1 (PRO vs CON) 20 min

Moderator: Dr. Enrique Grande

Intravesical approaches vs systemic prioritization



Dr. Félix Guerrero

Uro-Oncology Specialist

Head of the Bladder Cancer Unit at the Department of Urology
Hospital Universitario 12 de Octubre, Madrid, Spain.

PRO: (intravesical devices)



Dr. Tom Powles

Specialist in Genitourinary Oncology

Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's
Hospital; Lead for Solid Tumour Research, London, UK.

CON: (systemic prioritization)

Debate 2 (PRO vs CON) 20 min

Moderator: Dr. Daniel Castellano

Conservative vs early radical approach in UTUC



Dr. Patrizia Giannatempo

Medical Oncologist
Istituto Nazionale dei Tumori (INT)
Milan, Italy

PRO: (conservative approach)



Dr. Morgan Roupret

Medical Oncologist
Sorbonne University
Paris, France

Radical approach

10 min – Interactive case + audience voting included.



10:00 – 10:30

SYMPOSIUM Reserved

TBD



10:30 – 11:00 – COFFEE BREAK

11:00 – 12:30

Perioperative Bladder Cancer – Personalizing Treatment
(Debate Edition)

Debate 1 (PRO vs CON) 30 min

Moderator: Dr. Andrea Apolo

ctDNA-guided decision-making: ready for prime time?



Dr. Tom Powles

Specialist in Genitourinary Oncology
Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's
Hospital; Lead for Solid Tumour Research, London, UK.

PRO



Dr. Michiel Van der Heijden

Medical Oncologist specialized in bladder cancer
Netherlands Cancer Institute
Amsterdam, Netherlands

CON

Debate 2 (PRO vs CON) 30 min

Moderator: Dr. Daniel Castellano

Organ preservation vs radical surgery



Dr. Patrizia Giannatempo

Medical Oncologist
Istituto Nazionale dei Tumori (INT)
Milan, Italy

PRO



Dr. Morgan Roupret

Medical Oncologist
Sorbonne University
Paris, France

CON

12:30 – 13:30

A consensus on the definition of clinical complete response (20 min talk + 10 minutes discussion)



Moderator

Dr. Enrique Grande

Medical Oncologist

Specialized in genitourinary and endocrine tumors, Madrid, Spain



Dr. Michiel Van der Heijden

Medical Oncologist specialized in bladder cancer
Netherlands Cancer Institute
Amsterdam, Netherlands

13:30 – 14:15

Clinical Case Tumor Board – Bladder Cancer

Case presenter

Dr. Enrique Grande

Panelists

Dr. Andrea Apolo

Dr. Félix Guerrero

Dr. Tom Powles

Dr. Andrea Necchi

Lunch Break – Innovation Corners
(Industry-led lunch symposia & networking zones)

BLOCK 2 – RARE & UNCOMMON GU TUMORS

Rapid-Fire: Rare GU Tumors – “What Matters in 2026”

Moderator: Dr. Andrea Apolo



Dr. Michiel Van der Heijden
Medical Oncologist specialized in bladder cancer
Netherlands Cancer Institute
Amsterdam, Netherlands

PENILE CANCER



Dr. Ignacio Durán
Medical Oncologist
Head of the GU Oncology Section, Hospital Universitario Marqués de Valdecilla
Santander, Spain

GERM-CELL TUMORS



Dr. Patrizia Giannatempo
Medical Oncologist
Istituto Nazionale dei Tumori (INT)
Milan, Italy

BELLINI/COLLECTING DUCT CARCINOMA



Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital
Barcelona, Spain

ADRENOCORTICAL CARCINOMAS

Audience Q&A



16:15 – 16:35 – COFFEE BREAK

BLOCK 3 – RENAL CELL CARCINOMA (RCC)

RCC Debates – The Unresolved Questions

Moderators: Dr. Andrea Apolo & Dr. Enrique Grande

Debate 1 (PRO vs CON)

Triplets upfront vs doublets strategy in 1st line



Dr. Guillermo de Velasco Oria

Medical Oncologist
Hospital Universitario 12 de Octubre
Madrid, Spain

PRO THE USE OF TRIPLETS



Dr. Roberto Iacovelli

Medical Oncologist
Fondazione Policlinico Agostino Gemelli IRCCS
Rome, Italy

PRO DE USE OF DOUBLETS

Debate 2 (PRO vs CON)

Single agents vs doublets strategy in 2nd line



Dr. Ignacio Durán

Medical Oncologist
Head of the GU Oncology Section, Hospital Universitario Marqués de Valdecilla
Santander, Spain

PRO DE USE OF SINGLE AGENTS



Dr. Manuela Schmidinger

Medical Oncologist
Medical University of Vienna
Austria

PRO THE USE OF DOUBLETS IN 2ND LINE

Debate 3 (PRO vs CON)

Non-clear RCC → individualized vs unified treatment models



Dr. Javier Puente

Medical Oncologist
Hospital Clínico Universitario San Carlos
Madrid, Spain

PRO



Dr. Roberto Iacovelli

Medical Oncologist
Fondazione Policlinico Agostino Gemelli IRCCS
Rome, Italy

CON

Adjuvant treatment with or without HIF-2-alpha inhibitors



Dr. Ignacio Durán

Medical Oncologist

Head of the GU Oncology Section, Hospital Universitario Marqués de Valdecilla Santander, Spain

PRO THE USE OF HIF-2ALPHA



Dr. Manuela Schmidinger

Medical Oncologist

Medical University of Vienna Austria

PRO THE USE OF PEMBROLIZUMAB SINGLE AGENT

Audience interaction: live polls after each debate

18:30

Networking Dinner by the Sea

JUNE 26TH 2026

Barlovento Room
Monte Igueldo Hotel

08:30 – 09:00

Morning Coffee & Day 1 Highlights

Summary led by Dr. Andrea Apolo & Dr. Enrique Grande

09:00 – 10:00

BLOCK 4 – PROSTATE CANCER

mHSPC in 2026: The Big Perspective Clash

Moderator Dr Neeraj Agarwal. Presentation of 2 clinical cases → audience voting

Debate 1 (PRO vs CON)

Molecular/metabolic profiling to guide therapy vs classical clinical stratification



Dr. Elena Castro

Medical Oncologist

Hospital 12 de Octubre Madrid, Spain

PRO



Dr. Juan Antonio Vallejo Casas

Nuclear Physician

Hospital Universitario Reina Sofía Córdoba, Spain

CON

Intensification for all vs doublets



Dr. Neeraj Agarwal

Medical Oncologist
Huntsman Cancer Institute, University of Utah
USA

PRO INTENSIFICATION



Dr. José Pablo Maroto Rey

Medical Oncologist
Hospital Sant Pau
Barcelona, Spain

IN FAVOR OF DOUBLETS



10:00 – 10:30

SYMPOSIUM


TBD

 10:30 – 11:00 – COFFEE BREAK

11:00 – 12:00

RAPID-FIRE SCIENCE IN PROSTATE CANCER


Moderator: Dr. Daniel Castellano



Dr. José Pablo Maroto Rey

Medical Oncologist
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain

MOLECULAR PROFILING UPDATE



Dr. Neeraj Agarwal

Medical Oncologist
Huntsman Cancer Institute, University of Utah
USA

OPTIMIZING TISSUE FOR TESTING



Dr. Elena Castro

Medical Oncologist
Hospital 12 de Octubre
Madrid, Spain

LIQUID BIOPSY & ctDNA IN PRACTICE

12:00 – 13:00

CLINICAL CASE TUMOR BOARD – MCRPC

Moderators: Dr. Andrea Apolo & Dr. Enrique Grande

Panelists:

**Dr. Juan Antonio Vallejo Casas, Dr. Elena Castro,
Dr. Neeraj Agarwal & Dr. José Pablo Maroto Rey**

Debate embedded:

- **When to switch treatments?**
- **Combine? Radiate? Sequence?**

13:00 – 13:30

FUTURE DIRECTIONS IN PROSTATE CANCER

Roundtable

Led by Dr. Andrea Apolo & Dr. Enrique Grande

Open microphones for audience & panelists.

13:30 – 14:30

CLOSING LUNCH & NETWORKING